Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | HTRA2 | O43464 | 8/20 | 0.47 |
| ▸ | HTRA1 | Q92743 | 8/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22618551 | 1.00 | ALB (0.52) | ALBFOLH1ESR1HTRA2HTRA1 | |
| SCHEMBL22618487 | 1.00 | ALB (0.52) | ALBFOLH1ESR1HTRA2HTRA1 | |
| SCHEMBL22618495 | 0.93 | ESR1 (0.52) | ALBFOLH1ESR1HTRA2HTRA1 | |
| SCHEMBL22618538 | 0.93 | ESR1 (0.52) | ALBFOLH1ESR1HTRA2HTRA1 | |
| SCHEMBL22618554 | 0.93 | ALB (0.52) | ALBFOLH1ESR1HTRA2HTRA1 | |
| SCHEMBL22618511 | 0.93 | ALB (0.52) | ALBFOLH1ESR1HTRA2HTRA1 | |
| SCHEMBL22618482 | 0.91 | HTRA2 (0.54) | ALBFOLH1ESR1HTRA2HTRA1 | |
| SCHEMBL22618483 | 0.91 | HTRA2 (0.54) | ALBFOLH1ESR1HTRA2HTRA1 | |
| SCHEMBL22618543 | 0.91 | HTRA2 (0.54) | ALBFOLH1ESR1HTRA2HTRA1 | |
| SCHEMBL22618493 | 0.91 | ALB (0.55) | ALBFOLH1ESR1HTRA2HTRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822318-B2 | Lactone-based probes and methods of use thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822318-B2 | Lactone-based probes and methods of use thereof | MRPL21, QPCTL, ARGLU1 | ALB 2831/4885FOLH1 137/4885ESR1 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.